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Abstract 
Non-invasive prenatal testing for single gene disorders is now clearly on the horizon. This new 
technology offers obvious clinical benefits such as safe testing early in pregnancy. Before 
widespread implementation it is important to consider the possible ethical implications. Four 
hypothetical scenarios are presented that highlight how ethical ideals of respect for autonomy, 
privacy and fairness may come into play when offering non-invasive prenatal testing for single 
gene disorders. The first scenario illustrates the moral case for using these tests for ‘information 
only’, identifying a potential conflict between larger numbers of women seeking the benefits of 
the test and the wider social impact of funding tests that do not offer immediate clinical benefit. 
The second scenario shows how the simplicity and safety of non-invasive prenatal testing could 
lead to more autonomous decision-making and, conversely, how this could also lead to 
increased pressure on women to take up testing. In scenario three we show how, unless strong 
safeguards are put in place, offering non-invasive prenatal testing could be subject to 
routinisation with informed consent undermined and that woman who are newly diagnosed as 
carriers may be particularly vulnerable. The final scenario introduces the possibility of a conflict 
of the moral rights of a woman and her partner through testing for single gene disorders. This 
analysis informs our understanding of the potential impacts of non-invasive prenatal testing for 
single gene disorders on clinical practice and has implications for future policy and guidelines 
for prenatal care. 
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Introduction  
The technology underpinning the development of non-invasive prenatal testing (NIPT) based on 
cell free fetal DNA (cffDNA) is advancing rapidly and the promise of accurately detecting 
aneuploidies and genetic conditions early in pregnancy using a maternal blood test is now being 
realised. The clinical benefit of NIPT is clear as the risk of miscarriage that accompanies current 
invasive methods of prenatal diagnosis will be avoided. It is important, however, to pause and 
consider the wider implications of offering these tests. The implementation of NIPT should not 
be solely dependent on the availability of the technology; stakeholder views are critical and the 
tests must be ethically justifiable. While many of the ethical issues that have been raised about 
NIPT are not new to prenatal diagnosis, the practical and potentially moral ‘advantages’ of NIPT 
resulting from no risk of miscarriage and potentially earlier testing do alter the choices 
presented to women and families, and to policy-makers. As a result, there is a corresponding 
change to the moral nature of prenatal diagnosis and screening programmes. 
 
Several commentators have drawn attention to the potential shift in the balance of ethical 
principles brought about by the implementation of NIPT.1-4 The issues raised include: the 
potential to undermine informed consent as women may not to give sufficient consideration to 
testing as NIPT is “just another blood test”; the risk of normalising testing as routine which again 
can negatively impact on informed consent; increased societal pressure to take up testing and 
to terminate an affected pregnancy; and misuse of NIPT to test for minor reasons.1-4 These 
concerns have also come to the fore in studies looking at stakeholder views of NIPD.5-8 Much of 
the discussion to date has focused on the application of NIPT within programmes for Down’s 
syndrome screening and diagnosis. In this paper we aim to show how general concerns about 
NIPT apply to testing for single gene disorders and highlight how some of the ethical 
considerations will relate specifically to this area of practice. To do this we use four hypothetical 
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cases studies to demonstrate how ethical ideals of respect for autonomy, privacy and fairness 
could potentially be adhered to or compromised.    
 
Prenatal diagnosis of single gene disorders 
Prenatal diagnosis is an option available to many couples with pregnancies at risk of single gene 
disorders and upward of 1500 prenatal tests for over 100 different genetic conditions are 
performed each year in the United Kingdom (UK).9 In many cases the prospective parents will 
already be aware that the pregnancy is at risk of a genetic condition as their own carrier status 
will have been established prior to conception. This may be the result of cascade testing when 
there is a family history of the condition; a previous child identified with a condition through 
newborn screening or symptoms detected in childhood; or, less frequently, preconception 
carrier screening programmes for conditions such as Tay-Sachs, cystic fibrosis or fragile X-
syndrome.10 For other parents, carrier status can come to light during pregnancy if a family 
history of a condition is newly established or through a prenatal carrier screening programme, 
such as haemoglobinopathy screening.11 It is also possible that ultrasound findings will indicate 
that a new mutation has arisen de novo for an autosomal dominant condition such as 
achondroplasia.12  
 
Prenatal diagnosis of single gene disorders has traditionally been dependent on the use of 
invasive diagnostic tests (chorionic villus sampling (CVS) and amniocentesis) which carry a risk 
of miscarriage of around 1%13 and can only be safely conducted after 11 weeks gestation. NIPT 
based on cffDNA present in the maternal plasma will allow women to have prenatal diagnosis 
using a blood test. The cffDNA is pregnancy specific as it is cleared from the circulation within 
30 minutes of delivery14,15 and can be detected from 5 weeks in pregnancy16 so that NIPT for 
single gene disorders could be feasible from early in pregnancy, although data indicate that it is 
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not reliable until after 7-9 weeks.17 Consequently, NIPT brings the possibility of both safer and 
earlier testing for couples at risk of single gene disorders.  
 
Only a small proportion (around 10%) of the cell free DNA that is present in the maternal 
circulation comes from the fetus and the vast majority is maternal in origin.18 This relatively low 
level of free fetal DNA has been a major barrier to the development of NIPT as it is difficult to 
determine what genetic information is specific to the fetus against the large background of 
maternal cell free DNA. For this reason the first clinical uses of NIPT have been limited to the 
identification of gene changes present in the fetus but not in the mother, because they were 
inherited from the father or because they arose as a result of a de novo mutation. Accordingly, 
one of the early successes of NIPT in clinical practice has been fetal sex determination for women 
at risk of having a child with a genetic condition that primarily affects a particular sex which is 
based on detecting the presence or absence of Y chromosome-specific sequences in the 
maternal plasma.19 NIPT for fetal sex determination is viewed positively by women who have 
had the test20,21 and has been show to be cost neutral.22  
 
The development of NIPT tests for single gene disorders is ongoing. NIPT has been used to 
diagnose several autosomal dominant conditions that are paternally inherited or have arisen de 
novo23 including, torsion dystonia24 and achondroplasia.12 In addition, NIPT has been used for 
excluding a paternal mutation in autosomal recessive conditions when parents carry different 
mutations, such as beta thalassaemia.25 The advent of new technologies such as next generation 
sequencing and digital PCR is expanding this outlook and proof-of-principle studies have clearly 
demonstrated that NIPT can be successfully applied to X-linked conditions26 and recessive 
conditions where parents carry the same mutation.27-29  
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Exploration of ethical issues 
In this paper we assume that prenatal testing in general is ethically acceptable, and look in detail 
at four hypothetical scenarios in which using NIPT to diagnose single gene disorders might 
impact upon ethical aspects of clinical practice. At present NIPT is only available clinically for the 
diagnosis of a very limited number of single gene disorders. For each of the scenarios described 
here we are assuming that the NIPT test is available, that it can be performed from 7 weeks 
gestation and that the accuracy is the same as for invasive testing (>99%).  
  
Hypothetical scenario 1 – A couple who wants to plan and prepare  
Anne and David are expecting their second child. Their first child has cystic fibrosis (CF), and 
they are therefore aware that they are both carriers of the condition. Anne and David agree 
that they would not terminate an affected fetus, but have asked their genetic counsellor 
whether they can have NIPT in order to prepare during pregnancy. 
 
CF is an autosomal recessive condition caused by mutations in the CFTR gene. CFTR is important 
for the movement of salt and water in and out of cells and people affected by CF have a build up 
of sticky mucus, particularly in their lungs and digestive system. There is no cure for CF, however, 
treatments have improved dramatically in recent years and life expectancy is now above 40 
years.  
 
For Anne and David, undergoing NIPT allows earlier diagnosis, without the risk of miscarriage 
and the associated anxiety, and without the physical discomfort of the invasive testing 
procedure.30 Depending on the result, NIPT will provide Anne and David with either early 
reassurance if the pregnancy is unaffected or time and space for preparation if the pregnancy is 
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affected. Similarly, the utility of having early knowledge about the pregnancy would also apply 
to those women who know they are at risk but do not already have an affected child.  
 
Research asking service users’ views about NIPT for fetal sex determination have shown that 
early reassurance is a welcome aspect of NIPT, and that finding out the fetus is at low risk  brings 
“peace of mind” and helps prospective parents enjoy a “normal” pregnancy earlier than would 
be possible with traditional invasive testing pathways.20 Conversely, if the fetus is affected Anne 
and David can start to prepare mentally and practically for raising a child with CF. Whilst this 
result is not what the couple would hope for, having a definitive answer early in pregnancy may 
imbue Anne and David with a sense of control and autonomy over their pregnancy as well as 
providing early relief from uncertainty. These are key attributes identified as patient-desired 
outcomes of genetic counselling31-33 that have been reported by women having NIPT for fetal 
sex determination.20 
 
Provided Anne and David are equipped (with the aid of genetic counselling) for both possible 
outcomes of the test, and provided they undergo the test through their own choosing, the 
provision of a diagnosis through NIPT is a wholly positive advancement. However, Anne and 
David’s particular situation is not insulated from wider ethical questions; assessing the 
advantages and disadvantages of using NIPT for information is only part of the picture. Any 
moral argument for implementing NIPT for testing for ‘information only’ (with no intention to 
terminate) in a state-funded healthcare system would have to include justification for directing 
limited national health resources towards this use when it will not change pregnancy 
management. This is particularly pertinent here, as women often feel ambivalent towards 
invasive testing due to the conflict between a desire for information and the risk of 
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miscarriage.34 The availability of NIPT and the possibility of genetic diagnosis with no risk of 
miscarriage may thus result in larger numbers of couples taking up testing for information only.  
 
Looking to the future where genome wide sequencing promises to allow the diagnosis of 
multiple genetic conditions with a single non-invasive test 29,35, it is possible that a panel of tests 
for common conditions could be offered to parents not already identified as carriers of a 
particular single gene disorder. In this setting there may be many parents who will want the 
reassurance of having prenatal screening but say that they would not choose to have a 
termination of pregnancy if the fetus is affected. As these tests could be offered to all pregnant 
women the result could be a significant increase in the numbers of people seeking testing for 
single gene disorders raising yet further questions about how to fund tests that would have no 
immediate clinical benefit.  Furthermore, questions such as whether women should be allowed 
to access testing ‘for information only’ through private providers and the subsequent reduction 
in equity of access that would result also needs to be considered. 
 
 
The issues that arise in any discussion of testing for information only will differ depending on 
the nature of the single gene disorder in question. For example, with CF if the parents are 
seeking testing without the intention to terminate there is no clear clinical benefit of knowing if 
the fetus is affected prior to birth. For a condition such as haemophilia, either genetic diagnosis 
or knowledge of fetal sex is critical to guide management of labour and delivery of males “at 
risk” of haemophilia. The use of NIPT for fetal sex determination for haemophilia has raised 
debate around the acceptability of offering tests in a state funded healthcare system when the 
immediate clinical benefit of the test is unclear. Using NIPT to determine fetal sex when this 
could be done via routine ultrasound at no extra cost later in pregnancy has resulted in some 
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clinical services in the UK only offering NIPT when it will change pregnancy management as they 
consider the additional cost is not balanced by clinical benefit.36 Indeed, in the UK, the regulatory 
body (the UK Genetic Testing Network) has not approved fetal sex determination using NIPT in 
pregnancies at risk of haemophilia for this reason.  However, others have argued that to meet 
patient need, it is important to take into account the wider variety of benefits associated with 
NIPT for carriers of haemophilia as they have described a number of psychological advantages 
of early testing.20 Consequently, it is important that policy makers consider how we measure the 
psychological benefits of testing alongside clinical utility and weigh up whether the non-clinical 
personal benefits justify the cost of the test. 
 
Denying NIPT to those testing for information only would in many cases involve differentiating 
between those who know in advance they would consider terminating an affected pregnancy, 
and those who know in advance they would not. Given that decision-making about prenatal 
testing and termination is not straight-forward, and women don’t always know how they will 
respond to the results until they are given20 the assumption that women could reliably predict 
their decisions in advance of receiving information seems flawed. Further, even if there was 
sound justification for measuring cost-effectiveness purely in terms of clinical outcome, or for 
prioritising the benefits of decisions about continuing or terminating a pregnancy over the 
benefits of being prepared, policymakers should consider that making such a distinction might 
imply NIPT was a resource for informing decisions about termination, rather than providing 
women with information about their pregnancies per se. 
 
Whether NIPT would be used more widely for information only will depend on at least three 
ethical considerations: i) whether the non-clinical outcomes are regarded as benefits when 
measuring cost-effectiveness; ii) whether it is deemed acceptable to offer NIPT only to those 
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women who declare they would consider termination on the basis of the results; iii) whether 
there are ever circumstances in which NIPT can be offered for information only when there is 
no clinical benefit.   
 
Hypothetical scenario 2 – A woman who changes her mind  
Katie has a two year old daughter and is now pregnant with her second child. Katie’s father has 
Becker muscular dystrophy (BMD) and she knows she is a carrier of the condition. Katie feels 
quite certain that she would be able to raise a child with BMD and would not terminate an 
affected fetus. When she was pregnant with her first child, Katie did not have prenatal testing 
because she did not want to put the pregnancy at risk and did not want to put herself in a 
position where she would have to make a decision about termination.   
 
When Katie speaks to her genetic counsellor she learns that NIPT is now available to diagnose 
BMD. Even though she initially did not want to take the test, she finds it difficult to decline as 
this new technology is just a blood test and freely available. Ultimately, she decides she ‘might 
as well’ take the test. The results show the fetus has the condition. After further consideration 
she changes her mind and opts for a termination.  
 
BMD is an X-linked recessive condition caused by mutations in the dystrophin gene. The 
dysprophin protein is important for muscle function and boys with BMD will have progressive 
muscle weakness and wasting. There is no cure and although the condition is very variable, 
someone affected by the condition is likely to be wheelchair bound from adolescence onwards 
and life expectancy is around 40-50 years of age. 
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It is widely accepted that a key goal of genetic counselling when offering prenatal testing, 
whether offered by a genetic counsellor or other appropriately trained healthcare professional, 
is to support women to make informed choices regarding their pregnancies, thus allowing the 
exercise of reproductive autonomy.37,38  When a person acts autonomously, she exercises an 
informed choice free from undue influence. Autonomy is compromised (and therefore informed 
consent is invalidated) whenever an individual’s decision is subject to coercion or illegitimate 
pressure. The relative ease and risk-free nature of acquiring information through NIPT has the 
dual opposing effect of allowing women to exercise their reproductive autonomy by removing 
one of the barriers (risk of miscarriage) to information, and potentially threatening autonomous 
decision-making if the very ease and safety of NIPT contributes to a feeling of pressure to take 
the test. Thus it is important to be aware that although people, like Katie, with experience of a 
particular condition in their family may be informed about the condition itself, their decisions 
regarding prenatal testing can be influenced by the types of tests they are presented with. 
 
There is continuing debate about whether widening the scope of prenatal testing  creates 
further options for autonomous decision-making or hinders reproductive autonomy by 
increasing pressure to make decisions,39 and putting further responsibility upon the prospective 
mother.40 It has been suggested that the medical procedures for prenatal testing “decentre 
parents as moral agents responsible for reproductive outcomes.”41 A woman’s decision about 
prenatal testing inevitably has heavy moral content, relating to her own wellbeing, the interests 
of her family, her moral obligations towards the unborn child, the message to the disabled 
community, and the impact of her decision on society. Many women will, to greater and lesser 
degrees, feel the burden of these decisions. In the context of invasive testing, there is an added 
consideration, namely the risk of miscarriage. It is possible that, by removing the risk of 
miscarriage, the fundamental experience of decision-making will change significantly and 
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women may feel undue pressure to take up NIPT. The possibility for increased pressure to take 
up NIPT has the potential to arise from a variety of sources, including how the information is 
conveyed, societal expectations, and the removal of reasons (risk of miscarriage) against testing. 
 
The possibility of increased societal pressure to test and terminate has been highlighted by 
health professionals5, women using NIPT for fetal sexing21 and the public in regard to NIPT.6 In a 
study conducted in the United States, health professionals perceived that patients faced strong 
social pressures to undergo prenatal testing and claimed that additional caution may be 
necessary to ensure these pressures do not have undue influence on patient decision-making 
around testing and termination of pregnancy.5 Similarly, Kelly et al.6 identified a concern 
amongst the general public in the UK that NIPT would promote attitudes towards ‘perfection’ in 
reproduction.  
 
It is also possible that the very existence of NIPT will prompt feelings of pressure to make use of 
this new technology. The suggestion that the availability of a particular technology can create a 
perceived need is one that has been raised before in the context of prenatal testing. 
Seavilleklein42  suggests that “the existence of the technology and the way it is portrayed creates 
the perception that it is a necessary part of prenatal care, not merely an optional one". The 
concern is that women who do not necessarily want testing or do not want to make decisions 
about termination of pregnancy may have difficulty declining NIPT which is easy to access and 
carries no risk to the fetus. For this reason, if reproductive autonomy is to be respected, it is 
critical that expert pre- and post-test counselling is provided to ensure that decision-making is 
in line with the parents’ values and beliefs.43,44 
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Finally, it is important to note that for Katie, whilst she may not have set out to make a decision 
about whether to terminate the pregnancy, she was nevertheless equipped with information 
that helped her make a decision which might actually have led to a better outcome for her and 
her family. Katie felt quite differently about her situation once she knew the diagnosis. If Katie 
was able to make an informed and considered decision based on that information, then arguably 
she was in a better position once she had the knowledge, even if she did not anticipate making 
this particular choice. 
 
Hypothetical scenario 3 – A newly diagnosed carrier  
Litsa is pregnant with her first child and her doctor has advised her to have a number of blood 
tests including routine haemoglobinopathy screening for her and her partner. At a later 
appointment Litsa is told that she and her partner are carriers of beta thalassaemia. Litsa is 
reeling from this news and when her doctor suggests that she has a blood test to diagnose the 
condition she immediately accepts. When the results come back they are positive and Litsa 
suddenly finds herself facing a decision about whether to continue the pregnancy. 
 
Beta thalassaemia is an autosomal recessive condition caused by mutations in the HBB (beta 
hemoglobin) gene which is involved in the production of the oxygen carrying molecule 
haemoglobin. In people affected by beta thalassaemia there is not enough normal haemoglobin 
and this results in severe anaemia. People with beta thalassaemia will need regular monitoring 
and treatment, such as blood transfusions, throughout their lives. 
 
One of the major concerns around the introduction of NIPT for aneuploidies has been the 
potential for a diagnostic blood test to become routinised and undermine informed consent.1,4,45 
This scenario demonstrates how these concerns might also apply in certain circumstances when 
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offering NIPT for single gene disorders. When women newly discover they are carriers of a single 
gene disorder during pregnancy they are pressed for time to make decisions about prenatal 
testing for a condition of which they were not previously aware they were at risk. Women who 
know they are carriers before conception commonly have a plan in mind about whether they 
will opt for prenatal testing and have time and space to think through decisions.20,46 Women 
whose carrier status is revealed during pregnancy, however, may be particularly vulnerable to 
inadvertently finding themselves on a pathway to diagnostic testing and a decision about 
whether to continue or terminate the pregnancy. In these cases the offer of a ‘simple blood test’ 
for diagnosis may undermine informed consent if women are not properly counselled. 
 
The World Health Organisation (WHO) encourage screening programmes for haemoglobin 
disorders.47 The National Health Service Sickle Cell and Thalassaemia Screening Programme was 
initiated in 2001 and aims to offer universal antenatal and newborn carrier screening.11 Research 
exploring parental experiences of the prenatal screening programme has highlighted difficulties 
in facilitating informed consent, demonstrating a clear need for parents to have better 
information and be better prepared for results. For example, one qualitative study found that 
many women did not realise they had had screening or had misunderstandings about the test.48 
Another concern that has been raised about the UK prenatal carrier screening programme 
comes from research with general practice physicians (GPs) in the UK which found that sickle 
cell and thalassaemia carrier screening offered through primary care is often presented as a 
routine test.49 In a parallel study of women’s views, women reported that GPs present the test 
in a positive light, encouraging women to undergo screening.50 This approach was not, however, 
necessarily viewed negatively by the women.50 With these existing concerns around gaining 
informed consent and routinisation of testing already present in existing prenatal carrier 
screening programmes, additional caution will be required when introducing NIPT into this 
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setting to ensure this test is not perceived as a routine next step following a positive carrier 
screening result.   
 
As tests become part of routine clinical practice they become normalised and harder to question 
or decline.51 Routinisation has been observed with ultrasonography whose use in prenatal care 
has been shown to undermine informed consent.52,53 Whilst ultrasonography was originally 
intended to assess gestational age, monitor fetal development and detect fetal anomalies, it is 
also now viewed as having an important emotional role in pregnancy because of the fetal-
maternal bonding that takes place from being able to visualise the fetus.54,55 As a result, it has 
been found that women have difficulty refusing it for fear of being judged irrational or 
irresponsible.51 Women’s trust in health services and health professional opinions may also lead 
them to take up tests that are viewed as a standard part of prenatal care.56 In addition, women 
may not fully understand the purposes for which an ultrasound scan is done and therefore are 
wholly unprepared for adverse findings.55,57 The concerns here are very similar to those raised 
for aneuploidy screening programmes, in which the pitfalls of NIPT for aneuploidy being offered 
as a routine test and the resultant threat to informed consent has been discussed at length.45,58 
This scenario demonstrates how this concern extends to NIPT for single gene disorders and again 
highlights the need for thorough counselling and consent procedures when NIPT is offered.  
 
Hypothetical scenario 4 – Partner refusing carrier testing  
Jasmine has known since childhood that she is a carrier of sickle cell disease. She has recently 
found out she is pregnant and would like her partner, Clive, to undergo carrier testing to see 
whether the fetus is at risk. Clive refuses carrier testing. The haemoglobinopathy nurse offers 
Jasmine NIPT for diagnosis. 
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Sickle cell disease is an autosomal recessive condition caused by a change in the HBB (beta 
hemoglobin) gene that results in the production of an abnormal form of haemoglobin 
(haemoglobin S) which affects the red blood cells, sometimes altering their normal disk-like 
shape, to a sickle-shape (longer, curved and pointed). This change can cause health problems 
such as episodes of pain or infections. Although the treatment for sickle cell disease has improved 
in recent years, this disease is still associated with significant morbidity and reduced life 
expectancy. 
 
As sickle cell disorder is an autosomal recessive condition, to be certain the pregnancy is at risk 
the carrier status of both parents must be known. Couples are not always in agreement about 
carrier testing or may not be ready to seek testing at the same time. For example, timely testing 
of partners when pregnant women are identified as carriers has been reported to be a major 
challenge for the UK Sickle Cell and Thalassaemia Screening Programme, where early 
identification of parental carrier status is seen as key to making less time-pressured decisions.59 
In this scenario, NIPT offers Jasmine a resolution of her uncertainty that does not involve waiting 
for her partner to change his mind, or risking miscarriage through invasive testing.  
 
Legally, in terms of human rights law, the ultimate decision-maker for whether to undergo any 
prenatal testing is Jasmine, on the basis that it is her body, her pregnancy and therefore her 
right to accept or decline relevant tests and information.60 In some circumstances, such as 
testing in conditions where diagnosis will impact on treatments administered during pregnancy, 
there would also be a moral case for the woman to make a decision in the best interest of her 
child. However, a decision to take up prenatal diagnosis is not without sacrifice; by testing 
without Clive’s permission, Clive’s privacy may be invaded if the fetus is found to be affected. 
This is not unusual in genetic testing, since genetic information about one person will often 
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reveal facts about a biological relation, which gives rise to competing  rights of individuals. 
Further, if the test results are disclosed to Clive without his permission, then this would violate 
his right not to know his carrier status. Ultimately, any protection of privacy may be short-lived 
if the pregnancy went to term, as in the UK newborns at risk of sickle cell disease are tested as 
knowledge of disease status can aid management to improve clinical outcomes.  
 
Clive’s right not to know61 is recognised in genetic practice, but in this case may impede on 
Jasmine’s rights. Assuming that Jasmine has a positive right62 to NIPT under these conditions, 
depriving her of the test on the grounds that it would be a violation of her partner’s right not to 
know, and an invasion of his privacy would be to put Clive’s rights above hers. In Jasmine’s case, 
the invasion of her partner’s privacy could be justified on the grounds that the information 
sought is primarily information that belongs to her, and the results only incidentally give 
information about her partner. Jasmine’s intention is to know whether her fetus has sickle cell; 
finding out about her partner’s carrier status is a foreseen but unintended consequence of this. 
These ethical arguments apply regardless of how the diagnostic test is performed (invasive or 
NIPT), but in the case of NIPT where there is no risk to the pregnancy the offer may be more 
appealing and more likely to be taken up.   
 
It has been argued that the shared nature of genetic information and the moral obligations of 
familial relationships invites a communitarian approach,63 which would steer a compromise 
between the competing principles of, on the one hand, (Clive’s) privacy and the right not to 
know, and, on the other hand, (Jasmine’s) right to knowledge about her fetus. Since NIPT would 
not necessarily reveal carrier status (if the result is negative) opting for NIPT over carrier testing 
may offer a compromise for respecting Clive’s right not to know his carrier status as far as 
possible without depriving Jasmine of her right to information about her pregnancy. There may 
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also be remaining concerns about the partner’s lack of involvement (particularly if the test result 
is positive), and an asymmetry in the parents’ level of knowledge. These are issues that should 
be addressed during genetic counselling. 
 
Conclusion 
Imagining the possible future uses of NIPT for single gene disorders is helpful in considering in 
advance the ethical implications for changes in practice. This is particularly important as the 
nature and scope of prenatal testing is rapidly changing and becoming increasingly complex. 
New techniques for more detailed testing such as Array CGH and genome wide sequencing are 
coming into practice and new ways of offering tests such as direct-to-consumer are playing a 
greater role. Accordingly, many of the issues described here are not unique to NIPT and will be 
pertinent for other areas of practice. If NIPT is expanded for use in the diagnosis of single gene 
disorders, policy and guidelines will have an important role to play in ensuring procedures are 
in place for good practice. What ‘good practice’ constitutes will largely be a matter for 
policymakers and professional bodies to decide, and this may vary between countries. We 
suggest that, if the wellbeing of the mother and potential child, fairness and respect for 
reproductive autonomy are central values driving prenatal testing, then practitioners and 
policymakers should continue to strive for consistent service provision, and high quality 
information-giving and counselling by genetic counsellors or other appropriately trained 
healthcare professionals who are uniquely placed to promote informed choice.64,65 Further 
consideration should be given to whether and how widely available NIPT should be for 
information only when there is no clinical benefit, and whether this should be state or privately 
funded, issues which are likely to vary between countries and which  may largely depend on the 
local economic state. 
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